A randomized controlled trial comparing the efficacy and safety of oral tofacitinib versus methotrexate in moderate to severe alopecia areata

My research hypothesis is that methotrexate is non-inferior to tofacitinib in treating moderate to severe alopecia areata. In our research, we evaluated the SALT score, Scalp hair assessment PRO score at every month, and DLQI, and PHQ scores at baseline, at 6 months and 9 months of study period. we also evaluated side effects of both drugs at each visit.本研究假说为：甲氨蝶呤（methotrexate）治疗中重度斑秃（alopecia areata）的疗效非劣于托法替布（tofacitinib）。在本研究中，我们每月对SALT评分（SALT score）及头皮毛发评估患者报告结局评分（Scalp hair assessment PRO score）进行评估，并于研究基线、第6个月及第9个月时，评估皮肤病生活质量指数（DLQI）与患者健康问卷评分（PHQ score）。此外，我们于每次访视时评估两种药物的不良反应。